USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation
Summary
The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.
What changed
This document is a USPTO patent application (US20260083754A1) filed on November 28, 2025, for novel orally disintegrating tablet compositions containing topically acting corticosteroids. The invention is aimed at treating gastrointestinal inflammation, with a specific focus on eosinophilic esophagitis, by utilizing corticosteroids adsorbed onto carriers like silicified microcrystalline cellulose.
As this is a patent application, it does not impose immediate compliance obligations or deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for GI inflammation. Companies in the pharmaceutical sector, particularly those involved in drug development for inflammatory conditions, should be aware of this patent filing as it may impact their intellectual property landscape and future product development strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS
Application US20260083754A1 Kind: A1 Mar 26, 2026
Inventors
Michael A. GOSSELIN, Jin-Wang LAI, Gopi M. VENKATESH
Abstract
The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
CPC Classifications
A61K 31/56 A61J 3/10 A61K 9/0056 A61K 9/2009 A61K 9/2018 A61K 9/2027 A61K 9/2054 A61K 9/2081 A61K 9/2095 A61K 45/06 B29C 43/003 B29C 43/006
Filing Date
2025-11-28
Application No.
19403674
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.